ライフサイエンス出版株式会社

FacebookTwitterInstagram
menu

Japanese Pharmacology & Therapeutics(JPT)

<<Back
Next>>

Vol. 52 No. 11 2024

■ REVIEW

Using “Compassionate Use of Unapproved Drugs” (CU) to deal with “Drug Loss” in Japan
─The process and positive results of realizing the CU’s landmark are useful in addressing regulatory issues─

A. Teraoka, et al.

Jpn Pharmacol Ther 2024 52(11)1283-301

■ ORIGINAL ARTICLES

Modulation of the ability to produce adiponectin from mouse adipocytes by glucosamine hydrochloride in vitro

A. Furuta, et al.

Jpn Pharmacol Ther 2024 52(11)1303-10


Pathological evaluation to elucidate the mechanism of taste disturbances in rats by multi‒kinase inhibitor, sunitinib

M. Todo, et al.

Jpn Pharmacol Ther 2024 52(11)1311-7


Effect of ergothioneine on the stress-induced mood states, stomach discomfort, and sleep quality in healthy volunteers experiencing stress
-A randomized, double-blind, parallel group comparison study-

N. Watanabe, et al.

Jpn Pharmacol Ther 2024 52(11)1319-35


Effectiveness of AQUASOLITA® jelly for water and electrolyte replenishment in healthy adult men with sauna‒induced dehydration of heatstroke
―A randomized, crossover clinical equivalence study with comparison against AQUASOLITA® solution―

T. Fujii, et al.

Jpn Pharmacol Ther 2024 52(11)1337-53


Effects of apple pectin consumption on relief of constipation and improvement of skin barrier function

M. Nakamura, et al.

Jpn Pharmacol Ther 2024 52(11)1355-64


Verification study of blood glucose level fluctuation by consumption of rice cooked in a carbohydrate‒cut rice cooker
―A randomized, double‒blind, crossover study―

Y. Shishinai, et al.

Jpn Pharmacol Ther 2024 52(11)1365-74


Efficacy of Garcinia indica extract against obesity on overweight healthy adults
―A randomized, double‒blind, placebo‒controlled, parallel‒group study―

K. Ogushi, et al.

Jpn Pharmacol Ther 2024 52(11)1375-83


Safety evaluation of long—term(12 weeks)or excessive intake of food containing Levilactobacillus brevis subsp. coagulans FERM BP—4693(Labre®

K. Shimomura, et al.

Jpn Pharmacol Ther 2024 52(11)1385-98